SSA Swiss Advisors AG Invests $4.23 Million in Johnson & Johnson (NYSE:JNJ)

Key Points

• SSA Swiss Advisors AG has invested approximately $4.23 million in Johnson & Johnson, acquiring 25,455 shares which now represent about 2.2% of its portfolio.
• Johnson & Johnson reported a quarterly earnings per share (EPS) of $2.77, beating estimates by $0.09 and generating revenue of $23.74 billion, reflecting a 5.8% increase year-over-year.
• The company recently announced a quarterly dividend of $1.30 per share, representing an annualized dividend yield of 3.09%.

SSA Swiss Advisors AG purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 25,455 shares of the company's stock, valued at approximately $4,232,000. Johnson & Johnson makes up approximately 2.2% of SSA Swiss Advisors AG's investment portfolio, making the stock its 9th biggest holding.

A number of other hedge funds have also recently bought and sold shares of JNJ. Conquis Financial LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson in the 4th quarter valued at $36,000. Highline Wealth Partners LLC raised its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth $49,000. Finally, Capital A Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $50,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock traded down $2.50 during mid-day trading on Thursday, hitting $164.76. 9,876,897 shares of the stock were exchanged, compared to its average volume of 8,007,298. The stock has a market capitalization of $396.81 billion, a price-to-earnings ratio of 17.62, a PEG ratio of 2.13 and a beta of 0.41. The business has a fifty day moving average price of $157.18 and a 200 day moving average price of $156.44. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the business earned $2.82 earnings per share. The company's quarterly revenue was up 5.8% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on JNJ shares. Bank of America upped their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, UBS Group raised their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.